UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

The Efficacy of IDegLira (Insulin Degludec/Liraglutide Combination) in Adults with Type 2 Diabetes Inadequately Controlled with a GLP-1 Receptor Agonist and Oral Therapy: DUAL III Randomized Clinical Trial

Diabetes therapy, 2017-02, Vol.8 (1), p.101-114

2017

Volltextzugriff (PDF)

Patient-reported outcomes from a randomized, crossover trial comparing a pen injector with insulin degludec versus a pen injector with insulin glargine U100 in patients with type 2 diabetes

Current medical research and opinion, 2019-09, Vol.35 (9), p.1623-1629

2019

Volltextzugriff (PDF)

Impact of baseline characteristics and beta‐cell function on the efficacy and safety of subcutaneous once‐weekly semaglutide: A patient‐level, pooled analysis of the SUSTAIN 1‐5 trials

Diabetes, obesity & metabolism, 2020-03, Vol.22 (3), p.303-314

2020

Volltextzugriff (PDF)

Efficacy and Safety of Insulin Degludec 200 U/mL and Insulin Degludec 100 U/mL in Patients with Type 2 Diabetes (Begin: Compare)

Endocrine practice, 2014-08, Vol.20 (8), p.785-791

2014

Volltextzugriff (PDF)

Insulin Degludec 200 Units/mL Is Associated With Lower Injection Frequency and Improved Patient-Reported Outcomes Compared With Insulin Glargine 100 Units/mL in Patients With Type 2 Diabetes Requiring High-Dose Insulin

Clinical diabetes, 2017-04, Vol.35 (2), p.90-95

2017

Volltextzugriff (PDF)

Effect of Insulin Degludec vs Insulin Glargine U100 on Hypoglycemia in Patients With Type 2 Diabetes: The SWITCH 2 Randomized Clinical Trial

JAMA : the journal of the American Medical Association, 2017-07, Vol.318 (1), p.45

2017

Volltextzugriff (PDF)

Semaglutide as a therapeutic option for elderly patients with type 2 diabetes: Pooled analysis of the SUSTAIN 1‐5 trials

Diabetes, obesity & metabolism, 2018-09, Vol.20 (9), p.2291-2297

2018

Volltextzugriff (PDF)

3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial

The Lancet (British edition), 2017-04, Vol.389 (10077), p.1399-1409

2017

Volltextzugriff (PDF)

Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes

The New England journal of medicine, 2017-08, Vol.377 (8), p.723-732

2017

Volltextzugriff (PDF)

Oral Semaglutide Versus Empagliflozin in Patients With Type 2 Diabetes Uncontrolled on Metformin: The PIONEER 2 Trial

Diabetes care, 2019-12, Vol.42 (12), p.2272-2281

2019

Volltextzugriff (PDF)

Comparison of insulin detemir and insulin glargine using a basal-bolus regimen in a randomized, controlled clinical study in patients with type 2 diabetes

Diabetes/metabolism research and reviews, 2009-09, Vol.25 (6), p.542-548

2009

Volltextzugriff (PDF)

Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial

European heart journal, 2015-05, Vol.36 (19), p.1186-1194

2015

Volltextzugriff (PDF)

Effect of Insulin Glargine Up-titration vs Insulin Degludec/Liraglutide on Glycated Hemoglobin Levels in Patients With Uncontrolled Type 2 Diabetes: The DUAL V Randomized Clinical Trial

JAMA : the journal of the American Medical Association, 2016-03, Vol.315 (9), p.898

2016

Volltextzugriff (PDF)

Consistent HbA1c and Body Weight Reduction with Semaglutide Independent of Diabetes Duration—SUSTAIN 1-5 and 7 Patient-Level Meta-analysis

Diabetes (New York, N.Y.), 2018-07, Vol.67 (Supplement_1)

2018

Volltextzugriff (PDF)

Efficacy and safety of mirogabalin (DS-5565) for the treatment of diabetic peripheral neuropathic pain: a randomized, double-blind, placebo- and active comparator-controlled, adaptive proof-of-concept phase 2 study

Diabetes care, 2014-12, Vol.37 (12), p.3253-3261

2014

Volltextzugriff (PDF)

Efficacy and safety of nebivolol and valsartan as fixed-dose combination in hypertension: a randomised, multicentre study

The Lancet (British edition), 2014-05, Vol.383 (9932), p.1889-1898

2014

Volltextzugriff (PDF)

Semaglutide Reduces Body Weight Across Baseline BMI Subgroups Across SUSTAIN 1–5

Canadian journal of diabetes, 2017-10, Vol.41 (5), p.S6

2017

Volltextzugriff (PDF)

14 - Semaglutide Reduces Body Weight Across Baseline BMI Subgroups Across SUSTAIN 1–5

Canadian journal of diabetes, 2017-10, Vol.41 (5), p.S6-S6

2017

Volltextzugriff (PDF)

Effect of Insulin Degludec Versus Insulin Glargine U100 on Hypoglycemia in Hispanic Patients With Type 2 Diabetes: Results From the SWITCH 2 Trial

Clinical diabetes, 2019-01, Vol.37 (1), p.73-81

2019

Volltextzugriff (PDF)

TREATMENT INTENSIFICATION WITH INSULIN DEGLUDEC/INSULIN ASPART TWICE DAILY: RANDOMIZED STUDY TO COMPARE SIMPLE AND STEP-WISE TITRATION ALGORITHMS

Endocrine practice, 2016-05, Vol.22 (5), p.546-554

2016

Volltextzugriff (PDF)

Intensification of IDegAsp Twice Daily (Adding Insulin Aspart vs. Switching To Basal–Bolus): Exploratory Randomized Trial in Type 2 Diabetes

Diabetes therapy, 2017-02, Vol.8 (1), p.197-205

2017

Volltextzugriff (PDF)

Twice-daily dosing of a repaglinide/metformin fixed-dose combination tablet provides glycaemic control comparable to rosiglitazone/metformin tablet

Diabetes, obesity & metabolism, 2009-09, Vol.11 (9), p.865-873

2009

Volltextzugriff (PDF)

Twice-daily and three-times-daily dosing of a repaglinide/metformin fixed-dose combination tablet provide similar glycaemic control

Diabetes, obesity & metabolism, 2009-10, Vol.11 (10), p.947-952

2009

Volltextzugriff (PDF)

PROCLAIM: pilot study to examine the effects of clopidogrel on inflammatory markers in patients with metabolic syndrome receiving low-dose aspirin

Texas Heart Institute journal, 2009, Vol.36 (6), p.530-539

2009

Volltextzugriff (PDF)

Spondylitis: a clue to hypoparathyroidism

Annals of internal medicine, 1969-05, Vol.70 (5), p.995

1969

Volltextzugriff (PDF)

1 – 25 von 31

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(24)
Mit Volltextzugriff
(25)

Publikationsform

Artikel
(31)

Sprache

Englisch
(31)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(21)
Science & Technology
(21)
Humans
(18)
Female
(16)
Male
(16)
Middle Aged
(15)
Diabetes
(13)
Adult
(11)
Diabetes Mellitus, Type 2 - Drug Therapy
(11)
Endocrinology & Metabolism
(10)
Aged
(9)
Clinical Trials
(9)
Diabetes Mellitus, Type 2 - Blood
(8)
General & Internal Medicine
(8)
Insulin
(8)
Medicine, General & Internal
(8)
Double-Blind Method
(7)
Treatment Outcome
(7)
Diabetes Mellitus
(6)
Hypoglycemia
(6)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

The Efficacy of IDegLira (Insulin Degludec/Liraglutide Combination) in Adults with Type 2 Diabetes Inadequately Controlled with a GLP-1 Receptor Agonist and Oral Therapy: DUAL III Randomized Clinical Trial

Patient-reported outcomes from a randomized, crossover trial comparing a pen injector with insulin degludec versus a pen injector with insulin glargine U100 in patients with type 2 diabetes

Impact of baseline characteristics and beta‐cell function on the efficacy and safety of subcutaneous once‐weekly semaglutide: A patient‐level, pooled analysis of the SUSTAIN 1‐5 trials

Efficacy and Safety of Insulin Degludec 200 U/mL and Insulin Degludec 100 U/mL in Patients with Type 2 Diabetes (Begin: Compare)

Insulin Degludec 200 Units/mL Is Associated With Lower Injection Frequency and Improved Patient-Reported Outcomes Compared With Insulin Glargine 100 Units/mL in Patients With Type 2 Diabetes Requiring High-Dose Insulin

Effect of Insulin Degludec vs Insulin Glargine U100 on Hypoglycemia in Patients With Type 2 Diabetes: The SWITCH 2 Randomized Clinical Trial

Semaglutide as a therapeutic option for elderly patients with type 2 diabetes: Pooled analysis of the SUSTAIN 1‐5 trials

3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial

Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes

Oral Semaglutide Versus Empagliflozin in Patients With Type 2 Diabetes Uncontrolled on Metformin: The PIONEER 2 Trial

Comparison of insulin detemir and insulin glargine using a basal-bolus regimen in a randomized, controlled clinical study in patients with type 2 diabetes

Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial

Effect of Insulin Glargine Up-titration vs Insulin Degludec/Liraglutide on Glycated Hemoglobin Levels in Patients With Uncontrolled Type 2 Diabetes: The DUAL V Randomized Clinical Trial

Consistent HbA1c and Body Weight Reduction with Semaglutide Independent of Diabetes Duration—SUSTAIN 1-5 and 7 Patient-Level Meta-analysis

Efficacy and safety of mirogabalin (DS-5565) for the treatment of diabetic peripheral neuropathic pain: a randomized, double-blind, placebo- and active comparator-controlled, adaptive proof-of-concept phase 2 study

Efficacy and safety of nebivolol and valsartan as fixed-dose combination in hypertension: a randomised, multicentre study

Semaglutide Reduces Body Weight Across Baseline BMI Subgroups Across SUSTAIN 1–5

14 - Semaglutide Reduces Body Weight Across Baseline BMI Subgroups Across SUSTAIN 1–5

Effect of Insulin Degludec Versus Insulin Glargine U100 on Hypoglycemia in Hispanic Patients With Type 2 Diabetes: Results From the SWITCH 2 Trial

TREATMENT INTENSIFICATION WITH INSULIN DEGLUDEC/INSULIN ASPART TWICE DAILY: RANDOMIZED STUDY TO COMPARE SIMPLE AND STEP-WISE TITRATION ALGORITHMS

Intensification of IDegAsp Twice Daily (Adding Insulin Aspart vs. Switching To Basal–Bolus): Exploratory Randomized Trial in Type 2 Diabetes

Twice-daily dosing of a repaglinide/metformin fixed-dose combination tablet provides glycaemic control comparable to rosiglitazone/metformin tablet

Twice-daily and three-times-daily dosing of a repaglinide/metformin fixed-dose combination tablet provide similar glycaemic control

PROCLAIM: pilot study to examine the effects of clopidogrel on inflammatory markers in patients with metabolic syndrome receiving low-dose aspirin

Spondylitis: a clue to hypoparathyroidism

Suchergebnisse filtern